anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The intricate relationship between viruses and epilepsy involves a bidirectional interaction. Certain viruses can induce epilepsy by infecting the brain, leading to inflammation, damage, or abnormal electrical activity. Conversely, epilepsy patients may be more susceptible to viral infections due to factors, such as compromised immune systems, anticonvulsant drugs, or surgical interventions. Neuroinflammation, a common factor in both scenarios, exhibits onset, duration, intensity, and consequence variations. It can modulate epileptogenesis, increase seizure susceptibility, and impact anticonvulsant drug pharmacokinetics, immune system function, and brain physiology. Viral infections significantly impact the clinical management of epilepsy patients, necessitating a multidisciplinary approach encompassing diagnosis, prevention, and treatment of both conditions. We delved into the dual dynamics of viruses inducing epilepsy and epilepsy patients acquiring viruses, examining the unique features of each case. For virus-induced epilepsy, we specify virus types, elucidate mechanisms of epilepsy induction, emphasize neuroinflammation's impact, and analyze its effects on anticonvulsant drug pharmacokinetics. Conversely, in epilepsy patients acquiring viruses, we detail the acquired virus, its interaction with existing epilepsy, neuroinflammation effects, and changes in anticonvulsant drug pharmacokinetics. Understanding this interplay advances precision therapies for epilepsy during viral infections, providing mechanistic insights, identifying biomarkers and therapeutic targets, and supporting optimized dosing regimens. However, further studies are crucial to validate tools, discover new biomarkers and therapeutic targets, and evaluate targeted therapy safety and efficacy in diverse epilepsy and viral infection scenarios.
This study will be a double-blind, randomized, 2-period, placebo-controlled, crossover study in healthy male and female subjects, performed at a single study center. Prior to inclusion, informed consent will be obtained. A brief medical history, including limited demographic data (gender, age and ethnicity) will be recorded, and eligibility for inclusion to the study will be established through a physical inspection of hands. Subjects will be shown how to complete the VAS. Visual analogue scale (VAS) as a research tool is frequently used for the assessment of pain severity and relief. VAS is easy to use and can be applied in a variety of settings; results are reproducible. VAS data are sensitive to treatment effects and can be analyzed using parametric statistical techniques. At each specific study visit, each subject will undergo a left-right comparison of two patch preparations, followed by a repeated test with an alternate combination of preparations. Thus, the study will comprise: Visit 1: EMLA Test Patch plus Placebo Patch OR EMLA Test Patch plus EMLA current Reference Patch. Visit 2: EMLA Test Patch plus EMLA current Reference Patch OR EMLA Test Patch plus Placebo Patch. There will be a washout period of at minimum of 4 calendar days between treatment periods (visits). No follow-up visit is needed. Any adverse event (AE) that is ongoing at the last visit will be followed up as appropriate.
Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
The trial is designed as multi-centre, non-randomized, single-group with a primary endpoint of death of convalescent plasma recipient in twenty eight days. We are planning to recruit 300 donor patients who recovered from COVID-19 and who offer to take part in an experiment based on the informed consent form. The recovery criteria involve body temperature normalization for more than 3 days, resolution of respiratory tract symptoms, and two consecutively negative results of SARS-CoV-2 RT-PCR assay test. The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots. The plasma recipients are adult patients diagnosed with COVID-19 according to the WHO Interim Guidance with confirmation by real-time RT-PCR assay The inclusion criteria to receive plasma assume to meet at least one of following : respiratory distress with tachypnoe ≥30 breaths per minute, oxygen level less than 94% in resting-state, partial pressure of oxygen (PO2) ≤ 80 mmHg. Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity. The recipient are going to undergo detailed clinical evaluation along with the assessment of biochemical parameters, complete blood count and inflammation indicators. The study involves a comprehensive assessment of the serological response of patients with different course of SARS-Cov-2 infection, as well as an analysis of the impact of the level of antibodies in the donor's plasma on the clinical response in patients with COVID-19. In addition, a comprehensive metabolomic analysis of donor and recipient blood was planned to identify prognostic and predictive factors. The endpoints include the safety of convalescents plasma transfusion, as well as the improvement of clinical symptoms and laboratory parameters.
PURPOSE: To obtain a skin-beautifying cosmetic effective for suppressing and improving the pigmentation of the skin by using an extract of SOUJUTSU (rhizome of Atractylodes lancea) as an active component. CONSTITUTION: This skin-beautifying cosmetic contains a liquid extract extracted from Atractylodes lancea (a plant of the family Composite) as an active component usually in an amount of 0.001-20wt.%, preferably 0.001-3wt.% in terms of dried solid. The extract is produced by pulverizing the whole grass or the leaf, stalk, rhizome, fruit, seed and/or flower of Atractylodes lancea or its dried product and extracting with a solvent (e.g. ethanol) at room temperature or under heating. The pigmentation suppressing effect can be improved by adding other conventional anti-inflammatory agent (e.g. allantoin), antioxidant (e.g. α-tocopherol), etc. It can be prepared in the form of O/W-type or W/O-type emulsified cosmetic, cream, cosmetic milky lotion, face lotion, oily cosmetic, pack, foundation, etc., by properly adding conventional cosmetic components.
Recurrence and metastasis stand as the primary contributors to mortality among patients with triple-negative breast cancer post-surgery, presenting a formidable clinical obstacle. Chemodynamic therapy (CDT), leveraging metal-ion-mediated Fenton-like reactions within the tumor microenvironment (TME), emerges as a promising avenue for addressing cancer metastasis. Despite recent progress, challenges such as tumor cell antioxidant defenses and epithelial-mesenchymal transition (EMT) impede the efficacy of CDT. Here, we introduce a novel approach using DNA-templated nanosheets (Dz-MnO2) that combine the functions of Mn2+-mediated CDT and DNAzyme-mediated gene therapy to suppress tumor growth and metastasis. The Dz-MnO2 nanosheets respond effectively to the TME, releasing Mn2+ and DNAzyme. The DNAzyme exhibits mRNA cleavage activity, specifically targeting oncogenic transcripts to reduce tumor progression. Mn2+ not only facilitates a Fenton-like reaction, enhancing the chemodynamic treatment effect, but also serves as a cofactor for DNAzyme, improving its catalytic efficiency. Concurrently, the nanosheets robustly silence the Twist1 gene, mitigating the EMT process and reinforcing CDT efficacy by suppressing apoptosis resistance. Results indicate that Dz-MnO2 nanosheets efficiently polarize M2-tumor-associated macrophages (TAMs) into M1-TAMs by locally mitigating tumor hypoxia via catalyzing the decomposition of H2O2 into O2. This collaborative strategy presents a promising approach to enhance CDT, effectively inhibiting tumor recurrence and metastasis.
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with heterogeneous and complex genetic underpinnings. Our previous microarray gene expression profiling identified significantly different neuregulin-2 gene (NRG2) expression between ASD patients and controls. Thus, we aimed to clarify whether NRG2 is a candidate gene associated with ASD. The study consisted of two stages. First, we used real-time quantitative PCR in 20 ASDs and 20 controls to confirm the microarray gene expression profiling results. The average NRG2 gene expression level in patients with ASD (3.23 ± 2.80) was significantly lower than that in the controls (9.27 ± 4.78, p < 0.001). Next, we conducted resequencing of all the exons of NRG2 in a sample of 349 individuals with ASD, aiming to identify variants of the NRG2 associated with ASD. We identified three variants, including two single nucleotide variants (SNVs), IVS3 + 13A > G (rs889022) and IVS10 + 32T > A (rs182642591), and one small deletion at exon 11 of NRG2 (delGCCCGG, rs933769137). Using data from the Taiwan Biobank as the controls, we found no significant differences in allele frequencies of rs889022 and rs182642591 between two groups. However, there is a significant difference in the genotype and allele frequency distribution of rs933769137 between ASDs and controls (p < 0.0001). The small deletion is located in the EGF-like domain at the C-terminal of the NRG2 precursor protein. Our findings suggest that NRG2 might be a susceptibility gene for ASD.
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a major global cause of mortality with limited effective treatments. Sirtuins (SIRT) are histone deacetylases that are involved in the regulation of redox and inflammatory homeostasis. Hence, the present study aims to investigate the role of SIRT-2 in modulating inflammation in a murine model of COPD.
METHODS: COPD in mice was established by cigarette smoke (CS) exposure for 60 days, and AK-7 was used as the specific SIRT-2 inhibitor. AK-7 (100 µg/kg and 200 µg/kg body weight) was administered intranasally 1 h before CS exposure. Molecular docking was performed to analyze the binding affinity of different inflammatory proteins with AK-7.
RESULTS: Immune cell analysis showed a significantly increased number of macrophages (F4/80), neutrophils (Gr-1), and lymphocytes (CD4+, CD8+, and CD19+) in the COPD, group and their population was declined by AK-7 administration. Total reactive oxygen species, total inducible nitric oxide synthase, inflammatory mediators such as neutrophil elastase, C-reactive protein, histamine, and cytokines as IL4, IL-6, IL-17, and TNF-α were elevated in COPD and declined in the AK-7 group. However, IL-10 showed reverse results representing anti-inflammatory potency. AK-7 administration by inhibiting SIRT-2 decreased the expression of p-NF-κB, p-P38, p-Erk, and p-JNK and increased the expression of Nrf-2. Furthermore, AK-7 also declined the lung injury by inhibiting inflammation, parenchymal destruction, emphysema, collagen, club cells, and Kohn pores. AK-7 also showed good binding affinity with inflammatory proteins.
DISCUSSION: The current study reveals that SIRT-2 inhibition mitigates COPD severity and enhances pulmonary therapeutic interventions, suggesting AK-7 as a potential therapeutic molecule for COPD medication development.
Several strategies have been devised to safely limit the use of thoracic imaging in patients suspected of pulmonary embolism (PE). However, they are based on different rules for clinical probability (CP) assessment, rendering their combination difficult. The four-level pulmonary embolism probability score (4PEPS) allows the combination of all other strategies using a single CP assessment. Methods and analysis: SPEED\&PEPS is a pragmatic cluster-randomized trial. After a preliminary period aimed to assess the possibility of inclusions and current practices in 23 Emergency Departments (ED), 20 EDs will be selected to participate to the active phase and randomization. Half of the centers will be allocated to the control group where physicians will be free to do as they see fit but they will be given the recommendation to apply a validated strategy. Half of the centers will be allocated to the interventional group where the physicians will be given the recommendation to apply the 4PEPS strategy. Patients with suspected PE will be included and followed for 90 days (anticipated number of patients to be included: 2560, 1280 in each arm). The primary objective will be to demonstrate that the application of the 4PEPS strategy by emergency physicians, in comparison to current practices, (i) does not increase the risk of serious events related to diagnostic strategies and (ii) significantly reduces the use of thoracic imaging. If successful, the SPEED\&PEPS trial will have an important impact for patients suspected of PE limiting their irradiation and for public health in substantial savings in terms of the direct cost of diagnostic investigations and the indirect cost of hospitalizations due to waiting times or delayed harmful effects. Funding: This work is funded by a French Public Health grant (PREPS-N 2019). The funding source plays no role in the study design, data collection, analysis, interpretation or the writing of the manuscript.
Transcriptome-wide association studies (TWAS) integrate gene expression prediction models and genome-wide association studies (GWAS) to identify gene-trait associations. The power of TWAS is determined by the sample size of GWAS and the accuracy of the expression prediction model. Here, we present a new method, the Summary-level Unified Method for Modeling Integrated Transcriptome using Functional Annotations (SUMMIT-FA), which improves gene expression prediction accuracy by leveraging functional annotation resources and a large expression quantitative trait loci (eQTL) summary-level dataset. We build gene expression prediction models in whole blood using SUMMIT-FA with the comprehensive functional database MACIE and eQTL summary-level data from the eQTLGen consortium. We apply these models to GWAS for 24 complex traits and show that SUMMIT-FA identifies significantly more gene-trait associations and improves predictive power for identifying "silver standard" genes compared to several benchmark methods. We further conduct a simulation study to demonstrate the effectiveness of SUMMIT-FA.
1,253,328. Gamma-globulin purification. UPJOHN CO. 18 March, 1970 [1 April, 1969; 3 March, 1970], No. 13046/70. Heading A5B. γ-globulin is purified from blood serum or plasma by separating γ-globulin from the other proteins in the serum or plasma by treatment with acrinol and removing acrinol from the resulting aqueous solution of the γ-globulin by contacting the solution with silica gel or a mineral silicate adsorbent and separating the adsorbent from the solution. The mineral silicate may be magnesium silicate or trisilicate, native calcium-magnesium silicate, talc heulandite, stilbite, chabazite, analcite or antrolite. An insoluble portion may be separated from the plasma or serum at a pH of from 7 to 8 by adding 3.5 to 5 volumes of 0.4 to w/v acrinol aqueous solution thereto, the solution recovered is mixed at pH 7 to 8 with human erythrocyte stroma or erythrocytes and from the solution recovered y-globulin is precipitated at pH 7 to 8 by adding acetone or a C 1-6  alkanol to provide an acetone or alkanol concentration of 20 to 30% u/v and the precipitate is recovered; the precipitated y-globulin is dissolved by pH 6.5 to 7.5 in phosphate buffer and the resulting solution is treated with silica gel, the solution not adsorbed upon the silica gel is recovered, passed over diethylaminoethyl cellulose equilibrated with phosphate buffer at pH 6.7, the diethylaminoethyl cellulose is eluted with phosphate buffer at pH 6.7 and the γ-globulin is recovered from the eluate in accordance with measurements of adsorbancies at 280 mÁ. The serum or plasma treated may be that of an animal treated with lymphoid tissue of human origin, from a horse treated with human thymocytes, or of human origin.
Novel compounds of the formula <FORM:1043859/C2/1> wherein R represents hydrogen, an alkyl, alkenyl or alkynyl group of up to 5 carbon atoms or an acyl group, and Z is a cyclo alkyl radical which includes a C3-C6 cyclo alkyl ring and contains at least 4C atoms where it partly consists of a cyclopropyl ring or at least 5C atoms where it partly consists of a cyclo butyl ring, are prepared by reacting compounds of the formula <FORM:1043859/C2/2> with an appropriate acid derivative such as a halide, anhydride or ester of a cycloalkane carboxylic acid and reducing the carbonyl group of the resulting morphinan of formula <FORM:1043859/C2/3> to a methylene group.  Alternatively, the same compounds may be condensed with a halide of the formula Hal-CH2-Z.  The product may be converted into an ether or ester and/or an acid addition salt.  The end products may have a morphinan or isomorphinan structure and may be obtained as racemic mixtures or in optically active form of which the (-) forms are preferred.  Pharmaceutical compositions having analgesic and antitussive activity and exhibiting an antagonistic action against the side effects of morphine contain as active ingredients compounds of the first above general formula.  The compounds may be used in tablets, dragees, suppositories, capsules or in liquid form and may be used for enteral or parenteral application.
Disclosed herein is method of treatment method wherein SHIP-deficiency is induced. The induction of SHIP deficiency leads to a rapid and significant expansion of myeloid suppressor cells (MySC) in peripheral lymphoid tissues. Consistent with expansion of MySC, splenocytes and LN cells from hosts with induced SHIP deficiency are significantly compromised in their ability to prime allogeneic T cell responses. These results demonstrate that SHIP regulates homeostatic signals for these immunoregulatory cells in adult physiology. Consistent with these findings, induction of SHIP deficiency prior to receiving a T cell replete BM graft abrogates acute GVHD. These findings indicate strategies that target SHIP could increase the efficacy and utility of allogeneic BMT and thereby provide a curative therapy for a wide spectrum of human diseases.
Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.
The galcanezumab arm will self-administer a subcutaneous injection of galcanezumab. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of galcanezumab 120 mg. The injections will be with a pre-loaded syringe containing galcanezumab.
A pasty manicuring enamel remover and a process for its preparation are disclosed. Conventional manicure removers mainly comprise a low-boiling solvent such as acetone, and hence they have the defects of leakage, evaporation, ignition, pollution, and serious solvent odor and are apt to damage nails and skin around them. This remover is prepared by swelling sodium montmorillonite modified with a high-boiling solvent of propylene carbonate to cause gelation to thereby make it pasty and can overcome the above-described defects. Fats, oils, vitamins, water, etc. may further be added thereto to keep nails and skin around them healthy. The enamel remover is applied to nails to dissolve and remove enamel.
A dispenser for a viscous pharmaceutical composition comprises a tray (2), a support layer (3), a viscous pharmaceutically acceptable carrier (4) which optionally contains a medicament and a removable protector layer (9). The support layer (3) covers the base and at least two opposed sides of the tray (2) and is capable of extending over the top edges of the said sides of the tray so that stiffening means (7, 8) may be fitted to the extended portion. The viscous pharmaceutically acceptable carrier (4) overlies the support layer (3) and may be lifted from the tray (2) on the support layer, using the stiffening means as handles. The removable protector layer (9) covers the exposed surface of the carrier on the tray. The carrier (4) adheres more strongly to the support layer (3) than to the protector layer (9) so that the latter may be peeled from the carrier (4) without disturbing it on the support layer. Preferably the carrier (4) contains from 1 to 12.5% by weight of antibacterial agent.
Procedure: Prone positioning The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring the implementation of prone positioning. The process of monitoring includes ECMO flow and vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation. Each session should last between 16 to 24 hours.
1345676 The antibiotic A-4696 ELI LILLY & CO 24 Feb 1972 [25 Feb 1971] 8697/72 Heading C2A The invention comprises an antibiotic designated A-4696 whose hydrochloride salt is a white crystalline substance soluble in water and insoluble in common organic solvents, has a m.p. greater than 220‹ C.; has an electromeric titration curve in 66% by weight aqueous dimethylformamide approximating a straight line with a slope of about 0À14 from pH 6À0 to pH 13À0; has the approximate composition 51À33% C; 5À79% H; 5À46% N; 30À96% 0; 6À72% Cl; has an apparent M.W. of 1158 as determined by vapour pressure osmometry; has a specific rotation at 25‹ C. at the sodium D line of -42À3‹ (C=1, H 2 O); has an ultraviolet absorption spectrum in acidic and neutral solutions at 276 mÁ with an extinction coefficient E<SP>1%</SP> km of 45, and in a basic solution a single absorption maximum at 300 mÁ with an extinction coefficient E<SP>1%</SP> km of 65, and has an infra-red absorption spectrum as shown in Fig. 1. A method of producing the antibiotic A-4696 comprises cultivating the organic Actinoplenes sp. strain ATCC. 23342, in a liquid culture medium containing assimilable sources of carbon, nitrogen and inorganic salts under submerged aerobic conditions until a substantial amount of antibiotic activity is imparted by the organism to the culture medium. The invention also comprises a pharmaceutical composition which contains antibiotic A-4696 or a pharmaceutically acceptable salt thereof in conjunction with a pharmaceutically acceptable excipient or carrier. Further, a method of treating bacterial infections in warm blooded animals, excluding man, comprises the administration of the antibiotic A-4696, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. Still further a method of producing weight gain in growing poultry comprises feeding the poultry a feed composition containing the antibiotic A-4696 or a pharmaceutically acceptable salt thereof in conjunction with a carrier.
[GB1345676A]